Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.
dc.contributor.author | Gelderblom, H | |
dc.contributor.author | Blay, J | |
dc.contributor.author | Seddon, B | |
dc.contributor.author | Leahy, Michael G | |
dc.contributor.author | Ray-Coquard, I | |
dc.contributor.author | Sleijfer, S | |
dc.contributor.author | Kerst, J M | |
dc.contributor.author | Rutkowski, P | |
dc.contributor.author | Bauer, S | |
dc.contributor.author | Ouali, M | |
dc.contributor.author | Marreaud, S | |
dc.contributor.author | van der Straaten, R | |
dc.contributor.author | Guchelaar, H | |
dc.contributor.author | Weitman, S | |
dc.contributor.author | Hogendoorn, P | |
dc.contributor.author | Hohenberger, P | |
dc.date.accessioned | 2014-03-05T10:41:13Z | |
dc.date.available | 2014-03-05T10:41:13Z | |
dc.date.issued | 2014-01 | |
dc.identifier.citation | Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study. 2014, 50 (2):388-96 Eur J Cancer | en |
dc.identifier.issn | 1879-0852 | |
dc.identifier.pmid | 24215845 | |
dc.identifier.doi | 10.1016/j.ejca.2013.10.002 | |
dc.identifier.uri | http://hdl.handle.net/10541/313657 | |
dc.description.abstract | Brostallicin is a DNA minor groove binder that has shown activity in patients with soft tissue sarcoma (STS) failing first-line therapy. The present study assessed the safety and efficacy of first-line brostallicin in patients with advanced or metastatic STS >60 years or not fit enough to receive combination chemotherapy. A prospective explorative pharmacogenetic analysis was undertaken in parallel. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to European journal of cancer (Oxford, England : 1990) | en |
dc.title | Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study. | en |
dc.type | Article | en |
dc.identifier.journal | European Journal of Cancer | en |
html.description.abstract | Brostallicin is a DNA minor groove binder that has shown activity in patients with soft tissue sarcoma (STS) failing first-line therapy. The present study assessed the safety and efficacy of first-line brostallicin in patients with advanced or metastatic STS >60 years or not fit enough to receive combination chemotherapy. A prospective explorative pharmacogenetic analysis was undertaken in parallel. |